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Evidence on the long-term risk of HIV infection in individuals taking HIV post-exposure
prophylaxis remains limited. In this retrospective data linkage study, we evaluate the
occurrence of HIV infection in 975 individuals who sought post-exposure prophylaxis in a
tertiary hospital between 2007 and 2013. Using privacy preserving probabilistic linkage, we
link these 975 records with two observational databases providing data on HIV events
(Zurich Primary HIV Infection study and the Swiss HIV Cohort Study). This enables us to
identify 22 HIV infections and to obtain long-term follow-up data, which reveal a median of
4.1 years between consultation for post-exposure prophylaxis and HIV diagnosis. Even
though men who have sex with men constitute only 35.8% of those seeking post-exposure
prophylaxis, all 22 events occur in this subgroup. These findings should strongly encourage
early consideration of pre-exposure prophylaxis in men who have sex with men after a first
episode of post-exposure prophylaxis.
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Post-exposure prophylaxis (PEP) is a widely accepted mea-sure to prevent HIV transmission1, and has been an integralpart of Switzerland’s prevention program since 19972.
Although indication criteria for non-occupational PEP and drug
regimens may slightly differ across healthcare institutions, PEP is
commonly prescribed to individuals within 48–72 h after
unprotected anal or vaginal sexual exposure, with a HIV-positive
partner not on suppressive antiretroviral therapy, or with a
partner of unknown HIV-status belonging to groups at con-
siderable risk of HIV transmission (i.e., men who have sex with
men (MSM), sex workers, people using intravenous drugs, and
individuals from a region with high HIV prevalence (defined as
>10%))3. In individuals receiving PEP, 3-compound antiretroviral
therapy is administered for 4 weeks, and follow-up should include
testing for HIV at 3 months to exclude late seroconversions2,3.
Whilst PEP intake in itself generally results in favorable out-
come, some subgroups seem to remain at high risk for subsequent
HIV infection4,5. To date, evidence on the long-term risk of HIV
in PEP seekers remains limited and conflicting: HIV incidence
after PEP intake was found to range from 0.78 to 7.6 per 100
person-years, but these findings were partly driven by small
studies, conducted over short time periods (i.e., typically
6–12 months), and including exclusively MSM4–12. Although
large cohort studies with prolonged follow-up are needed to
better characterize populations with a higher long-term risk of
HIV infection, loss to follow-up often undermines the feasibility
of such studies.
One possible approach to mitigate loss to follow-up bias resides
in the linkage of different health-related databases13,14. Linkage
may be performed between different datasets using a common
unique identifier (e.g., linkage of electronic records between two
departments within a single institution), or using probabilistic
record linkage whenever unique identifiers are not available (e.g.,
linkage of records from two independent cohort studies)14.
Probabilistic linkage commonly uses variables considered as
personal identifying information, such as names or date of birth.
In recent years, linkage of personal identifying variables have
become increasingly challenging due to privacy protection laws,
thereby leading to the development of new methodological
approaches15. Among others, the Privacy Preserving Probabilistic
Record Linkage (P3RL) has been found to be a reliable method to
preserve confidentiality: after one-way data encryption by the
responsible datacenters, a third, independent party is involved to
perform probabilistic data linkage15.
The primary aim of this retrospective data linkage study was to
estimate the long-term risk of HIV infection in PEP seekers. More
specifically, we assessed the occurrence of HIV diagnoses until
October 2019 in individuals who sought PEP at a tertiary referral
hospital in Switzerland (University Hospital of Zurich—USZ)
between 2007 and 2013. To achieve this, we used a privacy pre-
serving data linkage method between 3 different databases. As
previous evidence suggests that sexual risk taking occurs in
phases lasting 12 to 24 months16, we hypothesized that HIV
infections would be clustered shortly after the time of PEP con-
sultation. We were also interested in characterizing subgroups at
higher risk of HIV infection, i.e., to assess their clinical pre-
sentation and to explore which factors were associated with long-
term risk of HIV diagnosis. Additional analyses aimed at asses-
sing whether the decision to prescribe PEP at the time of PEP
consultation was appropriate.
Results
Data linkage. Of 975 records included in the PEP-USZ database,
15 were identified as potential links in the USZ-specific part of the
SHCS or in the ZPHI Study (Fig. 1). Of these, 3 were further
excluded since these individuals were diagnosed with HIV at PEP
consultation. Thus, internal linkage retrieved 12 records of PEP
seekers diagnosed with HIV.
Probabilistic record linkage retrieved 34 potential pairs. Of
these, we excluded 10 further records: 9 were potential links,
which—after further assessment of patient chart with the
responsible centers—did not constitute true matches, and in 1
individual, HIV was diagnosed at PEP consultation. Of the
remaining 24 potential links, 14 were further discarded, since these
records were already identified through internal linkage. Thus, 10
Fig. 1 Flow diagram illustrating the data linkage process. Of 975 records included in the PEP-USZ database, internal linkage yielded 12 records. Ten
additional records were retrieved through external linkage. Thus, data linkage resulted in the identification of 22 HIV infections among individuals seeking
PEP between 2007 and 2013. PEP: post-exposure prophylaxis; USZ: university hospital of Zurich.
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additional verified records of PEP seekers diagnosed with HIV
were retrieved using probabilistic linkage with the SHCS.
Occurrence of HIV infections and characteristics of PEP see-
kers. Combining records from internal and external linkages
resulted in the identification of 22 HIV infections: all 22 links
were participants enrolled in the SHCS (12 USZ-specific, 10 non-
USZ), of which 7 were also included in the ZPHI. Evidence of
HIV infection was thus found in 2.3% (22/971, 95%CI 1.48 to
3.43) of the initial PEP seekers cohort. Characteristics of indivi-
duals included in the cohort are presented in Table 1.
Compared to PEP seekers without evidence of HIV infection,
those diagnosed with HIV were all MSM (100% versus 34.4%,
p-value= <0.0001—Table 1). Although not reaching statistical
significance, repeated PEP intake, either in the past or during
study duration, differed between HIV outcome status. When only
MSM were considered, the proportion of individuals with
evidence of HIV infection reached 6.3% (22/348, 95%CI 4.17
to 9.43).
Clinical trajectories of PEP seekers diagnosed with HIV.
Figure 2 illustrates the clinical trajectories of PEP seekers diag-
nosed with HIV (n= 22). The median time between the last PEP
consultation and HIV diagnosis was 4.1 years (IQR: 2.3–6.4). In
most cases, the possible infection window was shorter than 2
years: the median time between the earliest possible infection date
and HIV diagnosis was 6.4 months (IQR: 2.1–20.8) (Fig. 3—panel
a). All 22 individuals were diagnosed in Zurich. Of these, 10 HIV
diagnoses were made outside the USZ (private practice setting).
In-depth review of the SHCS and ZPHI data revealed that 9
individuals (40.9%) presented clinical signs compatible with
primary HIV infection (i.e., acute or recent infection): 7 were
enrolled in the ZPHI Study, and 2 presented a time difference
between negative and positive HIV tests of less than 90 days
Table 1 Characteristics of individuals seeking PEP at the University Hospital of Zurich between 2007 and 2013.
Overall n= 971a Presumed HIV negative n= 949 HIV positive n= 22 p-value
Ageb, median [IQR] 32 [26 – 38] 32 [26 – 38] 32 [26 – 40] 0.745
Sex, male, n (%) 797 (82.1) 775 (81.7) 22 (100) 0.021
Swiss nationality, n (%) 684 (70.4) 670 (70.6) 14 (63.6) 0.483
MSM, n (%) 348 (35.8) 326 (34.4) 22 (100) <0.0001
Repeated PEP, n (%) 96 (9.9) 92 (9.7) 4 (18.2) 0.263
PEP indicated, n (%) 528 (54.4) 510 (53.7) 18 (81.8) 0.009
aRecords from individuals diagnosed with HIV at PEP visit (n= 4) were excluded from original database (n= 975), as described in Fig. 2.
bAge recorded at initial presentation (i.e., first PEP consultation)
PEP seekers without HIV diagnosis (n= 949) were compared to those with evidence of HIV infection (n= 22). The p values were obtained using the Man–Whitney U test for continuous variables and
the Fisher exact test for binary variables (two-sided tests). No adjustment for multiple comparisons was made (main study aim: descriptive). MSM: men who have sex with men; PEP: post-exposure
prophylaxis.
Fig. 2 Clinical trajectories of PEP seekers diagnosed with HIV (n= 22). Nine individuals presented clinical signs compatible with primary HIV infection
(i.e., acute or recent infection). PEP failure was possible in 6 cases: the start of the infection window occurred within 3 months of PEP consultation (cases
number 5, 9, 11, 18 and 22), or HIV was diagnosed at 3 months (case number 1). In case number 22, the estimated time of infection and medical history
were compatible with transmission 9 days before PEP consultation (part a). PEP: post-exposure prophylaxis.
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(Fig. 2). In 6 others (27.3%), the sequence of events did not allow
to rule out PEP failure: in 5 individuals, the start of the infection
window occurred within 3 months of PEP consultation (i.e.,
infection possibly related to the event that triggered PEP—Fig. 2:
individuals number 5, 9, 11, 18 and 22, Fig. 3—panel b), and in
individual number 1, the HIV test at 3 months was found
positive. Detailed data review, however, revealed that individual
number 18 did not receive PEP (reason: no indication criteria),
and that in 2 individuals, there was evidence of repetitive sexual
exposures, thereby making PEP failure unlikely (i.e., number 9
and 22). Interestingly, in individual number 22, the estimated
time of infection and medical history were compatible with
transmission 9 days before PEP consultation (Fig. 2, part a). In-
depth review of the SHCS and ZPHI data did not identify PEP
consultations other than those retrieved by our linkage.
Factors associated with long-term risk of HIV diagnosis. We
aimed to explore whether specific factors were associated with a
long-term risk of HIV: some risk factors, however, were so strong
that they accounted for all outcome events (e.g., all HIV infections
occurred in MSM), thereby impairing meaningful multivariable
regression analysis. Other methodological approaches (i.e., firth
logistic regression17, which usually accounts for highly predictive
risk factors) did not yield meaningful results, as some degree of
data separation was still present.
We also assessed the validity of the PEP prescription algorithm:
compared to PEP seekers without evidence of HIV infection, those
diagnosed with HIV were more likely to have an indication for
PEP (81.8% in those with and 53.7% in those without evidence of
HIV infection, p-value = 0.009—Table 1). Univariable regression
analysis confirmed this association (OR 3.87, 95%CI 1.43 to 13.49)
and results remained consistent after adjustment for repetitive
PEP seeking (OR 3.72, 95%CI 1.37 to 12.99).
Expected false-negative proportion yielded by data linkage. To
estimate the expected false-negative proportion yielded by our
method, we performed a simulation of our linkage using two pre-
existing registries. In this simulation study, 5.4% of false-negative
pairs were expected.
Discussion
In this retrospective data linkage study including a large and
diverse PEP seeker population, we found that HIV infections
occurred several years after PEP consultation, i.e., much later
than originally assumed. Even though MSM constituted only
35.8% of PEP seekers, infections were found exclusively in this
subgroup. Clinical indicators, such as repetitive PEP seeking or
indication for PEP, were associated with subsequent HIV
infection.
According to evidence on sexual behavior, sexual risk taking in
HIV-negative MSM seems to follow distinct patterns over time: in
a longitudinal analysis of data from the Multicenter AIDS cohort
Study16, individuals deemed at moderate risk of seroconversion
presented phases of risky behavior that lasted on average
12 months, whilst those deemed at high risk exhibited phases of
24 months. Thus, considering PEP seeking as a marker of sexual
risk taking, we assumed that outcome events would be clustered 12
to 24 months after PEP seeking. Surprisingly, however, most HIV
events in our study occurred several years after PEP consultation.
Our study suggests thus that phases of risk may persist for longer
periods than originally assumed, or that some trajectories may
include recurrent phases of risk. Large cohort studies enrolling
HIV-negative individuals at considerable risk of seroconversion—
such as the SwissPrEPared cohort study (NCT03893188)—will
bring a better understanding of sexual behavior and risk trajec-
tories over time.
Repetitive PEP seeking has been widely regarded as an indica-
tion for the prescription of pre-exposure prophylaxis (PrEP)18,19.
This is consistent with our findings, where repeated PEP intake,
either in the past or during study duration, differed between HIV
outcome status. In our study, however, HIV events were found to
occur exclusively in MSM, which raises the additional question
whether MSM should be encouraged to transition to PrEP as early
as after a first PEP episode. Early transition is also supported by
the fact that, compared to HIV incidence rates in the overall MSM
population of Zurich (average 2010–2013: 39 per 10,000)20, rates
retrieved from our study were higher in PEP-seeking MSM (70.5
per 10,000) and in MSM with repetitive PEP seeking (81.1 per
10,000; assuming that all HIV events were captured, and that all
participants presumed HIV negative were still at risk at the time of
analysis—Supplementary table 1). Although some institutions
Fig. 3 Infection window and possible PEP failures: distribution among PEP seekers diagnosed with HIV (n= 22). a Histogram showing the distribution
of time between the earliest possible infection date and HIV diagnosis (orange bars). In 17 cases, the possible infection window was shorter than 2 years.
b Histogram showing the distribution of time between PEP consultation and the start of the infection window (dark blue bars). PEP failure was possible
in 6 cases (illustrated with *): the start of the infection window occurred within 3 months of PEP consultation (n= 5), or HIV was diagnosed at 3 months
(n= 1). PEP: post-exposure prophylaxis.
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may have already started considering first PEP-episodes in MSM
as an indication for PrEP (as it is currently the case at the USZ),
the exact timing of referral to PrEP programs is still lacking in
most national and international recommendations18,21,22. Find-
ings from our study may thus further contribute to closing the
knowledge gap regarding the timing of PEP to PrEP transition in
MSM22. More specifically, a first, successful PEP episode (i.e.,
completed without subsequent HIV infection) should trigger
eligibility screening for PrEP.
Fast tracking PEP-seeking MSM into PrEP programs is also
supported by the fact that HIV events occurred several years after
PEP consultation, which suggested either sustained or recurrent
risk over time. In both cases, PrEP use and—more importantly—
users participation in PrEP programs could be an effective
approach to provide tailored prevention measures to MSM pre-
senting varying risk patterns over time (e.g., daily versus inter-
mittent PrEP). Institutional efforts should be thus targeted at
linking and retaining PEP-seeking MSM in prevention programs
offering PrEP counseling, STI screening and other services related
to sexual health care. To that end, approaches similar to those
found effective for MSM engagement in HIV care—such as the
identification of vulnerable populations, knowledge of particular
sexual practices (e.g., chemsex), respectful attitude from health-
care providers, or well-defined strategies for linkage to care—
should be considered23.
This study investigated the long-term risk of HIV infection in
individuals seeking PEP. In contrast to most previously published
studies4–12, our study was larger and included a diverse PEP see-
kers population (heterogeneous transmission groups, i.e., inclusion
of both MSM and heterosexuals), thereby ensuring wider applic-
ability. We used data linkage to mitigate loss to follow-up bias and
were able to collect outcome data that occurred—in some cases—
more than 10 years after PEP consultation.
This study, however, has some limitations. A first issue is
related to the retrospective design, which may lead to outcome
misclassification (i.e., seropositive individuals misclassified as
HIV-negative). To minimize this bias, however, we linked data to
external cohorts showing high participation rates (SHCS: 84%)24,
and high representativeness of the overall HIV-positive population
in Switzerland (including 75% of individuals living with HIV on
antiretroviral therapy)25,26. This approach enabled us to nearly
double the sample of HIV events identified by internal linkage: of
22 included links, 10 were retrieved exclusively through external
linkage. Second, because the PEP database was not designed as a
cohort study (i.e., no systematic data collection), some endpoints
(such as possible PEP failures) were difficult to assess. Access to
data from two large ongoing cohort studies (SHCS and ZPHI),
however, enabled us to obtain a much more granular picture on
these endpoints and contributed to improve data quality. Third,
data collection for the PEP database stopped end of 2013, which
may have limited the representativeness of the PEP-seeker
population presented in this study, since recent trends—such as
the emergence of chemsex or the use of PrEP – could not be fully
captured by our analysis. With respect to the latter, however,
widespread PrEP use in Switzerland started relatively late (i.e.,
around 2018) compared to other countries, as supported by an
online survey performed in 2017 reporting PrEP use in only
82/1893 (4.3%) of the participants27. Thus, the lack of information
on PrEP use may only be relevant for a small fraction of events
that occurred in 2018 and later (4 out of 22 HIV events). Results
generalizability may have also been hampered by the fact that PEP
seeking outside the USZ was difficult to assess. Although there are
no surveillance data on the total of PEP prescriptions at the
regional level, empirical evidence and several surveys suggest that
the USZ was one of the main PEP providers in the Zurich area
during this time period. Most notably, a series of longitudinal
surveys among MSM found that between 2007–2014, PEP uptake
ranged between 2.6 and 8% (mean: 5%)28. According to a previous
report combining several data sources to estimate the size of local
MSM populations20, the number of MSM in the Zurich area was
16000 (95% credible interval: 14,300–16,500). Combining results
on PEP uptake with local MSM population estimates corre-
sponded to an estimated number of 416 to 1280 (mean: 800) PEP
prescriptions occurring in Zurich within that timeframe. This
suggests that the 348 MSM included in our dataset represent a
substantial proportion of the total MSM population seeking PEP
during the observation time. Additionally, in-depth analysis of the
SHCS and ZPHI (i.e., SHCS: data on previous antiretroviral
therapy [either PEP or antiretroviral therapy for HIV]; ZPHI: data
on previous PEP), however, did not identify PEP consultations
other than those retrieved by our linkage. Although this is only
valid for PEP seekers with HIV events, it may nonetheless indicate
that the USZ was one of the main PEP providers between 2007
and 2013. Fourth, because the HIV epidemic in Switzerland is
mainly driven by MSM29, and because heterosexuals tend to be
underrepresented in the SHCS25,30, outcome ascertainment bias
may have occurred to some extent. However, this risk of bias was
deemed low, since heterosexuals reluctant to participate to the
SHCS would also most likely decline data collection for the PEP-
USZ database, thereby leading to an underrepresentation on both
sides of the linkage. Fifth, when assessing the long-term risk of
HIV, we did not take into account potential differences in follow-
up time. This limitation, however, had no impact on the two main
findings of this paper, i.e., that all HIV infections occurred in
MSM (who presented a follow-up times distribution similar to
non-MSM PEP seekers—Supplementary Fig. 1) and that a con-
siderable fraction of infection events occurred several years after
PEP consultation. A time-to-event analysis was conducted to
explore HIV rates in some specific subgroups (Supplementary
Table 1). These findings, however, need to be interpreted with
caution, since the lack of systematic follow-up for outcome
ascertainment may have led to an underestimation of the number
of HIV events, and to an overestimation of the number of parti-
cipants considered at risk at the time of analysis. Hence the
provided incidence rate estimates are best interpreted as lower
bounds for the real incidence in these populations. Finally, our
linkage method only used a few discriminative variables, which
may increase the risk of false-negative and false-positive links
(since any mismatch due to data error would lead to discard a true
or keep a false potential pair, respectively). To address this, all 34
potential pairs retrieved through external linkage were further
assessed, thereby leading to the exclusion of 9 false-positive links.
Additionally, a simulation of our linkage using two pre-existing
registries estimated the proportion of false-negative at 5.4%.
Overall, the weaknesses of this study are thus counterbalanced by
its key strength: most notably, the linkage between 3 databases
provided detailed data on multiple transmission groups and long
follow-up times not available in other studies.
In this retrospective data linkage study, the proportion of PEP
seekers tested positive for HIV after PEP intake was 2.3%, and
this proportion reached 6.3% in MSM. This study identified that
most seroconversions occurred 4 years after PEP consultation,
thereby bringing long-term insights into the risk of contracting
HIV following PEP seeking. Those who seroconverted were all
MSM, which should strongly encourage early consideration of
PrEP in MSM after a first episode of PEP.
Methods
We followed the RECORD guidelines for the REporting of studies Conducted using
Observational Routinely collected health Data31. This data linkage study was
approved by the local ethical committee (canton of Zurich, Switzerland—Regis-
tration number: 2019-00033), as were the PEP database study (registration number:
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2013-0006) and the ongoing cohorts used for data linkage (Swiss HIV Cohort
Study (SHCS): registration number EK-793; Zurich Primary HIV Infection (ZPHI)
study: registration number: EK-1452).
Study design and setting. This is a retrospective study involving data linkage
between 3 pre-existing databases, i.e., the PEP-USZ database, the ZPHI and the
SHCS. The PEP-USZ database has been described elsewhere32: in brief, it consists
of data from 975 individuals who sought non-occupational PEP prescription at the
USZ between 2007 and 2013 (corresponding to 1051 consultations). For each PEP
consultation occurring within this timeframe, data routinely collected by the
attending physician were extracted from the USZ electronic patient record system
and entered in the PEP-USZ database (Supplementary Note 1). Data collection
occurred retrospectively (i.e., after 2013). The ZPHI is a prospective, monocentric
cohort study established in 2002 at the USZ, which follows longitudinally indivi-
duals aged ≥18 years with a documented primary HIV infection (i.e., acute or
recent HIV infection)33,34. As of July 2020, more than 450 patients were enrolled.
Finally, the SHCS is a prospective, multicentric cohort study enrolling HIV-
infected individuals aged ≥18 years in Switzerland since 198826. As of July 2020, the
SHCS included nearly 21,000 individuals, of which 9735 were still being actively
followed. The region of Zurich accounts for 7701 SHCS participants, with follow-
up data collected either at the USZ or in the private practice setting.
The PEP-USZ database was considered the main database, i.e., the 975 records
included in this database constituted the main study cohort. The other databases
were only used to obtain follow-up data through data linkage, i.e., to assess the
occurrence of HIV infection in PEP seekers.
Participants involved in this project all provided consent, either for the use of
their study data (ZPHI and SHCS cohort) or of their routinely collected clinical
data (PEP-USZ database). More specifically, the SHCS consent form describes the
possible further use of health-related data for research purposes and the linking of
participant data to other sources of health-related data. For the PEP-USZ database,
patients were asked at hospital presentation for PEP consultation to sign a form
describing the possible further use of their health-related data for research
purposes.
Data constituting the PEP-USZ database were collected using Microsoft Access;
Data constituting the Zurich Primary HIV study (ZPHI) and Swiss HIV Cohort
Study (SHCS) databases were collected using Microsoft Access and Oracle,
respectively.
Study participants. All HIV-negative individuals who sought non-occupational
PEP prescription between 2007 and 2013 at the USZ were considered eligible.
Individuals seeking PEP for non-consensual sex or those with a positive HIV test at
hospital presentation were not considered. No restriction regarding the adequacy of
PEP prescription or subsequent PEP intake were applied.
Study variables. The primary outcome was defined as the occurrence of a
documented HIV infection, using the following pre-specified criteria: (1) HIV
infection diagnosed at the USZ with subsequent enrollment in the ZPHI or
USZ-specific part of the SHCS (determined by internal data linkage) and/or (2)
enrollment in the non-USZ part of the SHCS (i.e., private practice setting in Zurich
or any other SHCS center in Switzerland, determined by external data linkage). For
each HIV infection, we retrieved date(s) of PEP consultation(s) and date of HIV
diagnosis.
We were also interested in establishing in each case a possible infection window,
which represented the time period between the earliest possible infection date and
HIV diagnosis. The earliest possible infection date was defined as the date of the
last documented (or self-reported) negative HIV test. In individuals with a
documented acute or recent infection (i.e., in those enrolled in the ZPHI), we used
the estimated time of infection instead of the last HIV-negative test. The estimated
time of infection was calculated by means of clinical and laboratory criteria, as
reported previously35. We also assessed the occurrence of possible PEP failures,
which were defined as events with an infection window starting within 3 months of
PEP consultation36.
To characterize subgroups with a higher long-term risk of HIV infection, the
following variables were retrieved: age, sex, nationality, group at higher risk of HIV
transmission (MSM), whether PEP was indicated at the time of PEP consultation
(according to local prescription algorithm), and repeated PEP intake. The latter was
defined as self-reported repetitive PEP seeking (elicited from medical history) and/
or identification of multiple PEP seeking visits during study period (2007-2013).
Adherence to PEP (i.e., prescribed but not taken, prescribed but inadequately
taken) was used to assess the plausibility of transmission events. All risk factors and
confounders were predefined and based on data availability from the pre-existing
PEP-USZ database32. Only factors related to individuals seeking PEP (as opposed
to the episodes triggering PEP consultation) were considered.
Data sources and linkage methods. As both the USZ-specific part of the SHCS
and the ZPHI share a common unique identifier with the PEP-USZ database, this
institutional linkage was defined as “internal linkage”. Linkage with the non-USZ
part of the SHCS (i.e., private practice setting in Zurich or any other SHCS center
in Switzerland), however, was defined as “external” and used the P3RL method
(Fig. 4)15.
This approach used a third party to perform probabilistic data linkage after
predefined variables were pre-processed and encrypted by the responsible centers
(i.e., USZ research team for the PEP-USZ database and the SHCS datacenter for the
non-USZ SHCS database). Record linkage was undertaken using an encrypted,
non-unique, personal identifying information (i.e., complete date of birth) and the
following plain linkage variables: (1) gender, (2) an anonymous code used in the
SHCS cohort (i.e., initial of the patient first name combined with the number of
characters of the first name, e.g., Alan = A4), and (3) only the initial of the patient
first name. The coherence of specific time variables was also considered during
linkage, i.e., HIV diagnosis could not occur before PEP consultation. Date of birth
encryption used a procedure based on Keyed-Hash Message Authentication Code
(HMAC), which handles common systematic errors such as swapping days with
months or number transpositions. Probabilistic record linkage was performed by
assigning weights to potential pairs fulfilling a predefined set of rules (i.e., matching
encrypted date of birth, gender, initial of first name, anonymous code, and time
plausibility). Three weight thresholds were defined to categorize potential pairs:
those with a total weight <70 were rejected; pairs with total weight between 70 and
89 were considered as “questionable” links, those between 90 and 99 as “possible”
and those ≥100 as “definite”37. Linkage probability was thus not only affected by
total weight, but also by the number of alternative links (i.e., links with match on
date of birth and gender only). Because the linkage procedure was based on only
one highly discriminative variable (date of birth), we contacted individual SHCS
centers to perform additional data checks for all non-rejected pairs. Finally, to
estimate the expected false-negative proportion yielded by the linkage method, we
performed a simulation study using two pre-existing registries (HIV data consisting
Fig. 4 Study design. Records retrieved from the PEP-USZ database were linked with 2 cohort studies, using a common unique identifier (internal linkage:
ZPHI and USZ-specific part of SHCS) or a privacy preserving probabilistic linkage (external linkage: SHCS, non-USZ part), with the aim to identify PLWH
(blue person). PEP: post-exposure prophylaxis; PLWH: person living with HIV; SHCS: Swiss HIV Cohort Study; USZ: University Hospital of Zurich; ZPHI:
Zurich Primary HIV Infection study.
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of 2,868 records, and Cancer Registry data consisting of 90,276 records). The
simulation linkage between these registries used the exact same variables as those
used in our study. The proportion of false negatives was estimated by comparing
the results of the simulation linkage study with a gold-standard, i.e., with the results
from a previous linkage performed between these registries using several highly
discriminative variables (such as date of birth, date of death, names, or place of
residence)15.
Statistical methods. We did not perform sample size calculations, as the size of
the PEP seekers cohort was defined by the fixed size of the available PEP-USZ
database (data from 975 individuals collected over 6 years).
The primary analysis was descriptive, i.e., we assessed the long-term occurrence
of HIV infection in USZ PEP seekers using data linkage. Categorical variables were
expressed as proportions, continuous as median and interquartile range. For the
assessment of HIV events with regard to the overall population or to specific
subgroups, proportions with their 95% confidence intervals (CI) were computed.
Depending on the number of outcome events, we planned to conduct
univariable and multivariable logistic regression to explore which factors were
associated with long-term risk of HIV diagnosis. Finally, we assessed the validity of
the PEP prescription algorithm, i.e., whether the algorithm used at the time of PEP
consultation was able to identify individuals presenting a long-term risk of HIV
infection. To achieve this, we determined the occurrence of HIV infection in those
for whom PEP was indicated and explored the association between PEP indication
and HIV infection using logistic regression. All statistical analyses were conducted
in R, version 3.6.1. Two-sided tests were performed, and a level of significance of
0.05 was used.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Datasets analyzed during the current study and used to generate Table 1, Figs. 2 and 3,
and supplementary information are not publicly available due to the sensitive nature of
the data yielded by this small, highly representative, individual-level dataset (see also:
http://www.shcs.ch/294-open-data-statement-shcs). Source data are thus not provided
with this paper. Investigators with a request for selected data should send a proposal to
the Swiss HIV Cohort Study (SHCS) address (www.shcs.ch/contact). The provision of
data will be considered by the Scientific Board of the SHCS and the relevant study team.
Data provision is subject to Swiss legal and ethical regulations, and will be detailed in a
material and data transfer agreement.
Code availability
Study protocol and code can be made available from the corresponding author (FH) on
reasonable request.
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